Navidea Biopharmaceuticals, Inc. announced Kenneth Berger, Ph.D., as Senior Regulatory Consultant, and the return of the Company's former Director of Regulatory Affairs, Richard McFerron. Navidea's former Chief Regulatory Officer, Dr. Michel Mikhail, is no longer with the Company. Dr. Berger brings decades of experience in regulatory, clinical, and quality management in biologics, pharmaceuticals, and medical devices to Navidea's regulatory team.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | 0.00% | 0.00% | -99.82% |
1st Jan change | Capi. | |
---|---|---|
-99.82% | 10T | |
+48.64% | 5.46TCr | |
-6.44% | 3.99TCr | |
+37.07% | 3.88TCr | |
+14.28% | 2.69TCr | |
-11.17% | 2.62TCr | |
-21.40% | 1.88TCr | |
+25.64% | 1.22TCr | |
+0.96% | 1.22TCr | |
+27.04% | 1.19TCr |
- Stock Market
- Equities
- NAVB Stock
- News Navidea Biopharmaceuticals, Inc.
- Navidea Biopharmaceuticals Announces Executive Changes